logo
Lupus anticoagulants and anticardiolipin antibodies
First isolation of actomyosin from a non-muscle cell
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? Yes
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No
Moderate dose oral anticoagulant therapy in patients with the antiphospholipid syndrome? No
Oral anticoagulation for the antiphospholipid antibody syndrome
A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)1
The skinny on treatment of venous thromboembolism in obesity
The influence of extreme body weight on clinical outcome of patients with venous thromboembolism
Life without histidine-rich glycoprotein
Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG)
Vitronectin
Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation
Cell-derived microparticles
Cell-derived microparticles contain caspase 3 in vitro and in vivo
Negative impact of depression on outcomes in patients with coronary artery disease
Molecular mechanisms of age-related regulation of genes
A model-based algorithm for the monitoring of long-term anticoagulation therapy
Safety, pharmacokinetics, and immunogenicity of single-dose rFXIII administration to healthy volunteers
Cardiovascular and thrombophilic risk factors for idiopathic sudden sensorineural hearing loss
Decreased plasma sensitivity to activated protein C by oral contraceptives is associated with decreases in plasma glucosylceramide
Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome
Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case–control study
Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence
Dose–response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement
The antigenic binding site(s) of antibodies to factor XII associated with the antiphospholipid syndrome
Soluble thrombomodulin activity and soluble thrombomodulin antigen in plasma
Functional analysis of recombinant Bβ15C and Bβ15A fibrinogens demonstrates that Bβ15G residue plays important roles in FPB release and in lateral aggregation of protofibrils
Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII
Post-transcriptional regulation of plasminogen activator inhibitor-1 by intracellular iron in cultured human lung fibroblasts—interaction of an 81-kDa nuclear protein with the 3′-UTR
In vivo and in vitro analysis of the human tissue-type plasminogen activator gene promoter in neuroblastomal cell lines
The role of plasminogen activator inhibitor type 1 in the inflammatory response to local tissue injury
Altered cytoskeleton organization in platelets from patients with MYH9-related disease
Lipid rafts are required in Gαi signaling downstream of the P2Y12 receptor during ADP-mediated platelet activation
The leptin receptor system of human platelets
Selective inducible nitric oxide synthase inhibition attenuates organ dysfunction and elevated endothelin levels in LPS-induced DIC model rats
Tissue factor enhances protease-activated receptor-2-mediated factor VIIa cell proliferative properties
Cloning, expression and functional characterization of the full-length murine ADAMTS13
Hemostatic abnormalities associated with obesity and the metabolic syndrome
Hemostatic abnormalities associated with obesity and the metabolic syndrome
Hemostatic abnormalities associated with obesity and the metabolic syndrome
Hemostatic abnormalities associated with obesity and the metabolic syndrome
Hemostatic abnormalities associated with obesity and the metabolic syndrome
Hemostatic abnormalities associated with obesity and the metabolic syndrome
Hemostatic abnormalities associated with obesity and the metabolic syndrome
Increased plasminogen activator inhibitor-1 levels in android obesity
Temporary relief of symptomatic Von Willebrand disease by multiple myeloma
HMR 3339, a novel selective estrogen receptor modulator, reduces concentrations of procarboxypeptidase U, an inhibitor of fibrinolysis. A randomized, placebo-controlled study in postmenopausal women
The poor quality of streptokinase products in use in developing countries
High prevalence of abnormal preoperative coagulation tests in patients with adolescent idiopathic scoliosis
Temporary inferior vena caval filter use in pregnancy
A monoclonal antibody that inhibits mouse tissue factor function
Is contrast venography a valid surrogate outcome measure in venous thromboembolism prevention studies?
The protective effect of the factor XIII Val34Leu mutation on the risk of deep venous thrombosis is dependent on the fibrinogen level
Ximelagatran and melagatran vs. low-molecular-weight heparin in major orthopedic surgery
A further face of the partial thromboplastin time APTT
Is citrate deficiency universal?
Delayed tirofiban-induced thrombocytopenia
Budd–Chiari syndrome in a paroxysmal nocturnal hemoglobinuria patient with coexistence of factor II and MTHFR mutations
More on
More on
More on
More on
ANNOUNCEMENTS
CORRIGENDUM